Yu Zhou

Dr. Yu Zhou

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJian-Hua Wang
Jian-Hua Wang
YTYu-Liang Tang
Yu-Liang Tang
ZGZhou Gong
Zhou Gong
Rohit JainRohit Jain
Rohit Jain
FXFan Xiao
Fan Xiao
XLXiaoguang Lei
Xiaoguang Lei
Chemical cross-linking of proteins coupled with mass spectrometry is widely used in protein structural analysis. In this study we develop a class of non-hydrolyzable amine-selective di-ortho-phthalaldehyde (DOPA) cross-linkers, one of which is called DOPA2. Cross-linking of proteins with DOPA2 is 60–120 times faster than that with the N-hydroxysuccinimide ester cross-linker DSS. Compared with DSS cross-links, DOPA2 cross-links show better agreement with the crystal structures of tested proteins. More importantly, DOPA2 has unique advantages when working at low pH, low temperature, or in the presence of denaturants. Using staphylococcal nuclease, bovine serum albumin, and bovine pancreatic ribonuclease A, we demonstrate that DOPA2 cross-linking provides abundant spatial information about the conformations of progressively denatured forms of these proteins. Furthermore, DOPA2 cross-linking allows time-course analysis of protein conformational changes during denaturant-induced unfolding.

20 January 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
QWQing Wang
Qing Wang
YZYu Zhou
Yu Zhou
JHJianhui Huang
Jianhui Huang
NHNiu Huang
Niu Huang
Since the first characterization of the 5-hydroxytryptamine 2B receptor (5-HT2BR) in 1992, significant progress has been made in 5-HT2BR research. Herein, we summarize the biological function, structure, and small-molecule pharmaceutical ligands of the 5-HT2BR. Emerging evidence has suggested that the 5-HT2BR is implicated in the regulation of the cardiovascular system, fibrosis disorders, cancer, the gastrointestinal (GI) tract, and the nervous system. Eight crystal complex structures of the 5-HT2BR bound with different ligands provided great insights into ligand recognition, activation mechanism, and biased signaling. Numerous 5-HT2BR antagonists have been discovered and developed, and several of them have advanced to clinical trials. It is expected that the novel 5-HT2BR antagonists with high potency and selectivity will lead to the development of first-in-class drugs in various therapeutic areas.

14 October 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
GLGudong Li
Gudong Li
WLWei Li
Wei Li
YXYuting Xie
Yuting Xie
XWXiaobo Wan
Xiaobo Wan
GZGuojun Zheng
Guojun Zheng
YZYu Zhou
Yu Zhou

14 May 2020 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
GLGudong Li
Gudong Li
WZWei Zhang
Wei Zhang
YXYuting Xie
Yuting Xie
YLYang Li
Yang Li
RCRao Cao
Rao Cao
YZYu Zhou
Yu Zhou

19 January 2024 in hLife
Verified
Journal Article
Open access
ZCZhao Chen
Zhao Chen
XRXintong Ren
Xintong Ren
YZYu Zhou
Yu Zhou
NHNiu Huang
Niu Huang

29 June 2022 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JXJiwei Xu
Jiwei Xu
CSCheng Shen
Cheng Shen
YXYuting Xie
Yuting Xie
BQBoxiang Qiu
Boxiang Qiu
XRXintong Ren
Xintong Ren
NHNiu Huang
Niu Huang